Roche Holding AG: Number of Employees 2012-2025 | RHHBY
Interactive chart of Roche Holding AG (RHHBY) annual worldwide employee count from 2012 to 2025.
- Roche Holding AG total number of employees in 2025 was 0, a 100% decline from 2024.
- Roche Holding AG total number of employees in 2024 was 103,249, a 0.34% decline from 2023.
- Roche Holding AG total number of employees in 2023 was 103,605, a 0.01% decline from 2022.
- Roche Holding AG total number of employees in 2022 was 103,613, a 2.67% increase from 2021.
| Roche Holding AG Annual Employee Count | |
|---|---|
| 2025 | N/A |
| 2024 | 103,249 |
| 2023 | 103,605 |
| 2022 | 103,613 |
| 2021 | 100,920 |
| 2020 | 101,465 |
| 2019 | 97,735 |
| 2018 | 94,442 |
| 2017 | 93,734 |
| 2016 | 94,052 |
| 2015 | 91,747 |
| 2014 | 88,509 |
| 2013 | 85,080 |
| 2012 | 82,089 |
| 2011 | 76,911 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |